AAU Institutional Repository

Assessment of Immuno-Hematological changes among HIV and TB/HIV co-infected patients taking Highly Active Antiretroviral Therapy for at least six months in Menelik II Referral Hospital, Addis Ababa, Ethiopia.

Show simple item record

dc.contributor.advisor Tsegaye, Aster (PhD)
dc.contributor.author Kasawmar, Esuyawkal
dc.date.accessioned 2020-11-22T07:37:37Z
dc.date.available 2020-11-22T07:37:37Z
dc.date.issued 2020-06
dc.identifier.uri http://etd.aau.edu.et/handle/123456789/23440
dc.description.abstract Background: Cytopenias are one of the most common complications in HIV and TB/HIV coinfected patients. Assessing immuno-hematological outcome is very essential for the management and care of people living with HIV and TB/HIV co-infection. Objective: To determine the Immuno-Hematological changes among HIV and TB/HIV co-infected patients taking HAART for at least six months at Menelik II Referral Hospital. Methods: This cross-sectional study was conducted on 338 HIV infected patients who have been taking HAART for at least six months. Socio-demographic, clinical, CD4+ T cells and hematological data at baseline and after at least 6 months on HAART were extracted from February to March 2019. Student t-test was used to compute the difference between baseline and current hematological and CD4+ T cells values. SPSS version 20 was used for data entry and analysis. P<0.05 was considered as statistically significant. Results: Of the total 338 individuals, 255 (75.4%) were infected with HIV only and 83 (24.6%) were TB/HIV co-infected. There was significant increase (p<0.05) in the mean CD4 (164.6 vs 317.1 cells/l), WBC (5.89 vs 6.49×10 3 /l), Hgb (13.07 vs 13.76g/dl), platelets (245 vs 265×10 /l), MCV (89.92 vs 96.13fl), MCH (30.25 vs 32.69pg) and a decrease in RBC (4.35 vs 4.25×10 /l) after six months of HAART. Compared to baseline, there was also significant decrease in the rate of Immunosuppression (CD4<350; 98.5 vs 88.5), anemia (39.9 vs 14.5%), leucopenia (22.2 vs 17.8%), neutropenia (11.5 vs 9.2%) and thrombocytopenia (16.9 vs 9.8%) after 6 months of HAART. When data was analyzed for HIV/TB co-infected patients separately, the effect of TB co-infection on HAART outcome was evident. The respective baseline and current values in this group were: CD4, 149.58 vs 294.72, WBC 5.83 vs 6.62, Hgb 12.25 vs 12.91, PLT 264.1 vs 262.9, RBC 4.22 vs 4.14, MCV 89.5 vs 92.6, MCH 29.54 vs 31.17 (P<0.05 for WBC, PLT, CD4, MCV). Rates of Immunosuppression was 98.8 vs 92.8%, anemia 51.8 vs 39.8%, leucopenia 21.7 vs 18.1%, neutropenia 10.8 vs 12.1%, thrombocytopenia 14.5 vs 12.0%. Besides, patients taking AZT based drugs had significantly higher MCV and MCH values (P<0.01) than those who did not. Conclusion: It is evident from this study that has shown significant improvements in immunohematological profiles after taking HAART for at least 6 months. The changes were more affected with TB co-infection suggesting further investigation considering HAART adherence. 3 6 en_US
dc.language.iso en_US en_US
dc.publisher Addis Abeba University en_US
dc.subject HAART, AZT, TB/HIV co-infection, CD4 T cells, Anemia, Thrombocytopenia, Leucopenia, Neutropenia. en_US
dc.title Assessment of Immuno-Hematological changes among HIV and TB/HIV co-infected patients taking Highly Active Antiretroviral Therapy for at least six months in Menelik II Referral Hospital, Addis Ababa, Ethiopia. en_US
dc.type Thesis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search AAU-ETD


Browse

My Account